Erratum

Erratum for the Research Article: “Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists” by A. Gillis, A. B. Gondin, A. Kliewer, J. Sanchez, H. D. Lim, C. Alamein, P. Manandhar, M. Santiago, S. Fritzwanker, F. Schmiedel, T. A. Katte, T. Reekie, N. L. Grimsey, M. Kassiou, B. Kellam, C. Krasel, M. L. Halls, M. Connor, J. R. Lane, S. Schulz, M. J. Christie, M. Canals

See allHide authors and affiliations

Science Signaling  16 Feb 2021:
Vol. 14, Issue 670, eabf9803
DOI: 10.1126/scisignal.abf9803

Upon reading the manuscript entitled “Re-evaluating how low intrinsic efficacy and apparent bias for G protein activation relates to the improved side effect profiles of new opioid agonists” posted to bioRxiv by E. L. Stahl and L. M. Bohn, the authors of the Research Article “Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists” became aware of transcriptional errors in some of the tabulated data in the paper and the Supplementary Materials. In Table 3 of the paper, the pEC50 value corresponding to SR-17018 for β-arrestin recruitment in the presence of GRK2 [βARR(GRK2)] was incorrect. In addition, the SEM value for buprenorphine in the Rab5(GRK2) column of Table 3 was incorrect. In table S1 in the Supplementary Materials, the authors had mistakenly copied the values of the GPA assay into the cAMP column. Thus, both the GPA and cAMP assays had the same transduction coefficients and errors. In addition, the second part of table S1 was missing the bottom row, corresponding to the transduction coefficients of buprenorphine in the β-arrestin recruitment assays with and without GRK2 overexpression. None of these transcriptional errors in the tables affected any of the figures in the paper. The PDF and HTML (full text) have been corrected. The Supplementary Materials PDF has been corrected.

Stay Connected to Science Signaling

Navigate This Article